Hologic, Inc. (NASDAQ:HOLX) Stock Holdings Lessened by DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main

DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main reduced its position in Hologic, Inc. (NASDAQ:HOLX - Free Report) by 98.5% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 2,165 shares of the medical equipment provider's stock after selling 139,474 shares during the period. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main's holdings in Hologic were worth $156,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Venturi Wealth Management LLC raised its stake in shares of Hologic by 156.3% in the 4th quarter. Venturi Wealth Management LLC now owns 428 shares of the medical equipment provider's stock valued at $31,000 after purchasing an additional 261 shares in the last quarter. EverSource Wealth Advisors LLC increased its holdings in Hologic by 79.8% in the fourth quarter. EverSource Wealth Advisors LLC now owns 586 shares of the medical equipment provider's stock valued at $42,000 after buying an additional 260 shares during the last quarter. Smartleaf Asset Management LLC raised its stake in Hologic by 36.9% during the fourth quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider's stock valued at $43,000 after buying an additional 159 shares in the last quarter. Smithfield Trust Co raised its stake in Hologic by 160.0% during the fourth quarter. Smithfield Trust Co now owns 650 shares of the medical equipment provider's stock valued at $45,000 after buying an additional 400 shares in the last quarter. Finally, Sound Income Strategies LLC bought a new position in Hologic during the 4th quarter worth approximately $60,000. Hedge funds and other institutional investors own 94.73% of the company's stock.

Insider Activity

In other news, Director Martin D. Madaus bought 5,445 shares of the stock in a transaction that occurred on Wednesday, May 7th. The shares were purchased at an average cost of $55.24 per share, with a total value of $300,781.80. Following the completion of the acquisition, the director now directly owns 5,445 shares in the company, valued at approximately $300,781.80. The trade was a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 1.88% of the company's stock.

Hologic Stock Performance

Shares of NASDAQ:HOLX traded up $1.05 during trading hours on Friday, hitting $56.79. The stock had a trading volume of 2,768,388 shares, compared to its average volume of 2,122,465. The stock's fifty day simple moving average is $58.88 and its 200 day simple moving average is $67.68. The firm has a market capitalization of $12.66 billion, a price-to-earnings ratio of 17.91, a PEG ratio of 2.14 and a beta of 0.54. The company has a debt-to-equity ratio of 0.52, a quick ratio of 2.78 and a current ratio of 3.49. Hologic, Inc. has a 1-year low of $51.90 and a 1-year high of $84.67.

Hologic (NASDAQ:HOLX - Get Free Report) last issued its quarterly earnings data on Thursday, May 1st. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.02 by $0.01. The business had revenue of $1.01 billion during the quarter, compared to analyst estimates of $1 billion. Hologic had a return on equity of 19.72% and a net margin of 18.42%. The business's revenue for the quarter was down 1.2% compared to the same quarter last year. During the same period in the prior year, the company posted $1.03 EPS. Sell-side analysts anticipate that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on HOLX. Citigroup lowered their price target on Hologic from $80.00 to $70.00 and set a "neutral" rating for the company in a report on Tuesday, March 4th. Argus cut shares of Hologic from a "buy" rating to a "hold" rating in a report on Monday, March 3rd. Morgan Stanley reduced their price target on shares of Hologic from $77.00 to $65.00 and set an "equal weight" rating on the stock in a research report on Monday, May 5th. Raymond James reaffirmed an "outperform" rating and set a $71.00 price objective (down previously from $90.00) on shares of Hologic in a research report on Friday, May 2nd. Finally, Needham & Company LLC reiterated a "hold" rating on shares of Hologic in a research note on Friday, May 2nd. Twelve analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus target price of $77.42.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.